PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1833448
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1833448
Europe Diabetes Care Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
The Europe Diabetes Care Devices Market was valued at USD 14.5 billion in 2024 and is estimated to grow at a CAGR of 12% to reach USD 44.5 billion by 2034.
Alongside this, modern sedentary lifestyles marked by reduced physical activity and poor dietary habits, such as high consumption of processed foods and sugars, are contributing to a growing number of new diabetes diagnoses. As more people live with diabetes, there is a heightened need for reliable, easy-to-use devices that help patients monitor and manage their blood glucose levels effectively.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $14.5 billion |
| Forecast Value | $44.5 billion |
| CAGR | 12% |
Rising Adoption of Devices
The devices segment held a significant share in 2024, as patients and providers increasingly rely on advanced tools for accurate glucose monitoring and effective insulin delivery. This segment includes a wide range of products such as blood glucose meters, continuous glucose monitors (CGMs), smart insulin pens, and insulin pumps, each playing a vital role in day-to-day disease management. The growing availability of connected devices that integrate with mobile apps and cloud-based systems is transforming how patients track and share their health data.
Homecare to Gain Traction
The homecare segment generated robust revenues in 2024, fueled by rising patient preference for self-management and the broader shift toward decentralized healthcare in Europe. With diabetes requiring continuous monitoring and lifestyle adjustments, more patients are seeking solutions that allow for flexible, at-home disease management. The adoption of CGMs, portable insulin pumps, and digital health platforms is making it easier for individuals to monitor their glucose levels without frequent clinical visits.
Germany to Emerge as a Propelling Region
Germany diabetes care devices market held a sizeable share in 2024, supported by a robust healthcare system, high public awareness, and widespread access to advanced medical technologies. Germany's progressive reimbursement policies, particularly for CGMs and insulin pumps, continue to drive demand among both type 1 and type 2 diabetes patients. Additionally, strong physician advocacy for digital tools and early intervention strategies is fueling device adoption.
Major players in the Europe diabetes care devices market are DarioHealth, Medtronic, Ypsomed Holding, F. Hoffmann-La Roche, ARKRAY, Insulet, Sanofi, Dexcom, Nova Biomedical, Novo Nordisk, Ascensia Diabetes Care, Dr. Reddy's Laboratories, B. Braun Melsungen, Abbott Laboratories, Eli Lilly and Company, Bionime, Becton, Dickinson and Company.
To strengthen their foothold in the Europe diabetes care devices market, companies are implementing strategies that focus on innovation, partnerships, and regional expansion. Leading manufacturers are investing heavily in R&D to create integrated systems combining glucose monitoring, insulin delivery, and AI-driven insights. Strategic collaborations with digital health startups are helping bring data analytics and real-time tracking features into legacy devices.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Data mining sources
- 1.3.1 Country
- 1.4 Base estimates and calculations
- 1.4.1 Base year calculation
- 1.4.2 Key trends for market estimation
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.6 Forecast model
- 1.7 Research assumptions and limitations
Chapter 2 Executive Summary
- 2.1 Industry 3600 synopsis
- 2.2 Key market trends
- 2.2.1 Country trends
- 2.2.2 Product trends
- 2.2.3 End use trends
- 2.3 CXO perspectives: Strategic imperatives
- 2.3.1 Key decision points for industry executives
- 2.3.2 Critical success factors for market players
- 2.4 Future outlook and strategic recommendations
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.1.1 Supplier landscape
- 3.1.2 Value addition at each stage
- 3.1.3 Factor affecting the value chain
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of diabetes and obesity in Europe
- 3.2.1.2 Technological advancements in CGM and smart insulin pens
- 3.2.1.3 Supportive reimbursement policies and insurance coverage
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High cost of advanced devices and limited rural access
- 3.2.2.2 Rigorous regulatory framework
- 3.2.2.3 Data residency and privacy regulations
- 3.2.3 Market opportunities
- 3.2.3.1 Integrated care models combining CGM, insulin delivery, and telehealth
- 3.2.3.2 AI-enabled decision support and closed-loop insulin automation
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological advancements
- 3.5.1 Current technological trends
- 3.5.2 Emerging technologies
- 3.5.2.1 Non-Invasive glucose monitoring technologies
- 3.5.2.2 Nanotechnology applications
- 3.6 Diabetes epidemiology and disease burden analysis
- 3.6.1 Regional diabetes prevalence trends
- 3.6.2 Gestational diabetes prevalence
- 3.6.3 Complication rates and healthcare costs
- 3.7 Patent landscape analysis for diabetes device innovations
- 3.8 Clinical trial pipeline assessment for emerging technologies
- 3.9 Supply chain risk analysis for key device components
- 3.10 Patient behavior and technology adoption patterns in diabetes care devices
- 3.11 Reimbursement scenario
- 3.11.1 Coding and reimbursement
- 3.11.2 Reimbursement policies and public healthcare sector insurance coverage for insulin delivery systems
- 3.12 Pricing analysis, 2024
- 3.13 Future market trends
- 3.14 Gap analysis
- 3.15 Porter's analysis
- 3.16 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
- 4.7 Key developments
- 4.7.1 Mergers and acquisitions
- 4.7.2 Partnerships and collaborations
- 4.7.3 New product launches
- 4.7.4 Expansion plans
Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)
- 5.1 Key trends
- 5.2 Devices
- 5.2.1 Blood glucose monitoring devices
- 5.2.1.1 Self-monitoring blood glucose meters
- 5.2.1.2 Continuous glucose monitors
- 5.2.2 Insulin delivery devices
- 5.2.2.1 Insulin pumps
- 5.2.2.1.1 Tubed pumps
- 5.2.2.1.2 Tubeless pumps
- 5.2.2.2 Pens
- 5.2.2.2.1 Reusable
- 5.2.2.2.2 Disposable
- 5.2.2.3 Other insulin delivery devices
- 5.2.2.1 Insulin pumps
- 5.2.1 Blood glucose monitoring devices
- 5.3 Consumables
- 5.3.1 Testing strips
- 5.3.2 Lancets
- 5.3.3 Pen needles
- 5.3.3.1 Standard
- 5.3.3.2 Safety
- 5.3.4 Syringes
- 5.3.5 Insulin pumps consumables
Chapter 6 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Hospital
- 6.3 Ambulatory surgical centers
- 6.4 Diagnostic centers
- 6.5 Homecare
- 6.6 Other end use
Chapter 7 Market Estimates and Forecast, By Country, 2021 - 2034 ($ Mn)
- 7.1 Key trends
- 7.2 Europe
- 7.2.1 Germany
- 7.2.2 France
- 7.2.3 UK
- 7.2.4 Italy
- 7.2.5 Spain
- 7.2.6 Netherlands
- 7.2.7 Sweden
- 7.2.8 Belgium
- 7.2.9 Denmark
- 7.2.10 Finland
- 7.2.11 Norway
- 7.2.12 Lithuania
- 7.2.13 Latvia
- 7.2.14 Estonia
- 7.2.15 Russia
- 7.2.16 Poland
- 7.2.17 Switzerland
Chapter 8 Company Profiles
- 8.1 Abbott Laboratories
- 8.2 ARKRAY
- 8.3 Ascensia Diabetes Care
- 8.4 B. Braun Melsungen
- 8.5 Becton, Dickinson and Company
- 8.6 Bionime
- 8.7 DarioHealth
- 8.8 Dexcom
- 8.9 Dr. Reddy’s Laboratories
- 8.10 Eli Lilly and Company
- 8.11 F. Hoffmann-La Roche
- 8.12 Insulet
- 8.13 Medtronic
- 8.14 Nova Biomedical
- 8.15 Novo Nordisk
- 8.16 Sanofi
- 8.17 Ypsomed Holding
